No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:48:04.441Z. Latest historical point 2026-03-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:48:04.441Z. Latest historical point 2022-03-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:48:04.441Z. Latest historical point 2022-03-29.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:48:04.441Z. Latest historical point 2022-03-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for SAB Biotherapeutics, Inc. (SABS) stock was $2.97 as of Oct 6, 2026, 1:45 PM EDT, down 4.35% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +50.2% · 3-year avg -23.1%/yr · 5-year avg -50.2%/yr
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Biotechnology · Miami Beach, FL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.27
Revenue Est.
$125000.00
Last Quarter Results
EPS
$-0.28
vs Estimate
$-0.28
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SABS | $269.77M | $2.96 | -4.35% | +50.19% | -50.16% | N/A | N/A |
| 2RCKT | $269.65M | $2.47 | -5.38% | -17.07% | -38.33% | -23.48% | vs SABS |
| 3TMCI | $269.55M | $4.16 | -7.25% | -29.44% | -29.41% | N/A | vs SABS |
| 4FATE | $269.54M | $2.31 | -4.84% | +100.16% | -46.86% | -2.31% | vs SABS |
| 5SCTX | $266.68M | $16.48 | +1.67% | N/A | N/A | N/A | vs SABS |
| 6TLSI | $266.62M | $4.33 | -1.14% | -5.17% | -15.05% | N/A | vs SABS |
forward FY estimate
N/A
$0.00
vs Estimate
$125000.00
Consensus Rating
Based on 11 analysts
Average Price Target
$11.64
+292.5% upside
Low
$6.00
Current
$2.96
High
$16.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.29 | $-0.27 | $-0.24 | 4 |
| Quarter ending Dec 2026 | $-0.30 | $-0.27 | $-0.23 | 4 |
| Quarter ending Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Quarter ending Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.25 | $-1.21 | $-1.12 | 6 |
| FY 2027 | $-1.15 | $-0.80 | $-0.48 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $125000.00 | $125000.00 | $125000.00 | 1 |
| Quarter ending Dec 2026 | $125000.00 | $125000.00 | $125000.00 | 1 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $333333.00 | $333333.00 | $333333.00 | 5 |
| FY 2027 | $50000.00 | $50000.00 | $50000.00 | 5 |
